If you are at #ESMO25 have a look at our posters about #QoL and #PROs:
3152P by Delia Bellino about compliance with #QoL questionnaires in cancer clinical trials;
3153P by Giorgia Intilisano about #QoL results of new cancer drugs recently approved by European Medicines Agency
Today meet Gaia who is studying complex genomic profile of high-grade serous carcinomas. Her aim is to understand which alterations in cancer cells cause their clinical behaviour and their response and resistance to new targeted drugs for a more personalized approach for patients
ESMO congratulates the recipients of the 2023 Research Fellowships & the José Baselga Fellowship, celebrated today at the YO Fellowship session at #ESMO23.
👏 Gil Awada, Pasquale Lombardi, @MJ_Mair, @NatalieNgoi and @nadiasago, @MyriamChalabi
👉https://t.co/RyAli1aSn9
ESMO has announced the names of the 2023 fellowship awardees who will be celebrated during the YO Fellowship session at #ESMO23. The awardees are Pasquale Lombardi, @MJ_Mair, Gil Awada, @NatalieNgoi, and @nadiasago.
👉https://t.co/zVKOAc9lL4
@darioT_@AIOMtweet Such a great opportunity to meet and discuss about the future of research with friends and colleagues! And learning from your terrific talk was the icing on the cake 😎
Changing the treatment algorithm of Endometrial cancer...It is time for IO also in first-line!
Jaw-dropping results from ENGOT-EN6-NSGO/GOG-3031/RUBY #endometrialcancer#ESMOVirtualPlenary#gyncsm@myESMO@AACR
https://t.co/ZrMqdZrh9u
My own take home messages as a young clinician:
1⃣Negative studies can provide valuable information
2⃣Every sample which is kindly donated is unique and will add a piece to the puzzle
3⃣New questions need to be answered (& I can’t wait to see what is next!)
Phase 2 randomized trial of 140 pts with platinum-resistant ovarian high-grade serous carcinoma found addition of dual mTORC inhibitor vistusertib to weekly paclitaxel did not improve progression-free survival, overall survival, or response rate. https://t.co/AE1K5mn53w #GynCSM